Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain ...

Our lead product candidate, Halneuron ®, is in Phase 2b development as a non-opioid, Na V 1.7 inhibitor to treat pain conditions including the neuropathic pain associated with chemotherapy treatment.

Maxim Group LLC (“Maxim”) acted as the sole Book-Running manager for the Offering. Loeb & Loeb LLP acted as counsel to the Company, and Ellenoff Grossman & Schole LLP acted as counsel to Maxim for the ...